Showing papers in "Biology of Blood and Marrow Transplantation in 2006"
Fred Hutchinson Cancer Research Center1, University of Regensburg2, University of Michigan3, Harvard University4, Vanderbilt University5, Center for Drug Evaluation and Research6, Washington University in St. Louis7, University of Manchester8, Boston Children's Hospital9, University of British Columbia10, Johns Hopkins University11
TL;DR: The response definitions have been revised to reflect changes and are expected to enhance reliability and practical utility of these measures in clinical trials, including in the pediatric population.
489 citations
University of Washington1, National Institutes of Health2, Harvard University3, Johns Hopkins University4, University of Michigan5, University of Paris6, Columbia University7, Vanderbilt University8, University of Texas MD Anderson Cancer Center9, University of Arkansas for Medical Sciences10, University of British Columbia11
TL;DR: This consensus document provides an update for pathologists and clinicians about the interpretation of biopsy results and use of this information in the management of hematopoietic cell transplantation patients.
411 citations
TL;DR: The addition of ATG to cyclosporine/methotrexate provides significant protection against extensive chronic GVHD and chronic lung dysfunction, reduces late transplant mortality, and improves quality of life in patients undergoing unrelated donor transplantation.
302 citations
University of Texas MD Anderson Cancer Center1, University of Washington2, Harvard University3, Johns Hopkins University4, National Institutes of Health5, University of California, San Francisco6, Fred Hutchinson Cancer Research Center7, University of Cincinnati8, University of Minnesota9, University of British Columbia10
TL;DR: Recommendations are provided for prevention of infections, osteoporosis, and steroid myopathy and management of neurocognitive and psychosocial adverse effects related to chronic GVHD and its therapy.
283 citations
TL;DR: Recommendations are developed to offer care providers suggested screening and prevention practices for autologous and allogeneic HCT survivors.
270 citations
Ohio State University1, Center for International Blood and Marrow Transplant Research2, Georgetown University3, Memorial Sloan Kettering Cancer Center4, University of Waterloo5, National Marrow Donor Program6, Leiden University Medical Center7, Children's National Medical Center8, University of Minnesota9, Cincinnati Children's Hospital Medical Center10
TL;DR: Patients who received grafts from donors mismatching at the KIR ligand in the GVH or HVG direction and mismatched at HLA-B and/or C but matched at the kir ligand had similar rates of TRM, treatment failure, and overall mortality.
240 citations
TL;DR: Recipient homozygosity for HLA-B or -C epitopes that define KIR ligands is likely to be a predictive factor for leukemia relapse after myeloablative HCT from H LA-mismatched unrelated donors, but this effect was not observed in Hla-identical unrelated transplants.
202 citations
TL;DR: Cord blood transplantation should be considered as frontline therapy for young patients with lysosomal and peroxisomal storage diseases, and the results suggest cord blood donors are readily available for rapid transplantation.
186 citations
TL;DR: Organ doses are substantially lower than those associated with standard TBI and predict the potential to significantly reduce associated toxicities and allow for dose escalation, and the results suggest that this form of targeted TBI may have potential advantages over other forms of targetedTBI, such as radioimmunotherapy or bone-seeking radionuclide therapy.
186 citations
TL;DR: It is suggested that NST is a reasonable alternative for patients with advanced AML and MDS at high risk for complications after myeloablative transplantation, but that this benefit is negated by increasing treatment-related mortality.
184 citations
TL;DR: The results confirm the relevance of severe infectious complications as source of severe morbidity and NRM after volunteer unrelated donor hematopoietic stem cell transplantation in adults, but suggest that CBT recipients have a similar risk of dying from an infection if an accurate selection of a cord blood unit is done.
Boston Children's Hospital1, City of Hope National Medical Center2, Stanford University3, Center for International Blood and Marrow Transplant Research4, University of Minnesota5, University of Toronto6, Columbia University7, Ohio State University8, Emory University9, University Hospitals of Cleveland10, Mayo Clinic11, Roswell Park Cancer Institute12, University of British Columbia13, Alfred I. duPont Hospital for Children14
TL;DR: For HLA-identical sibling allografts for acute lymphoblastic leukemia in CR2, there is an advantage in substituting etoposide for Cy or, when Cy is used, in increasing the TBI dose to > or =13 Gy.
TL;DR: Retrospective comparisons of clinical outcomes between unrelated cord blood and unrelated bone transplantation in children and adults have shown similar results, showing the value of this source of hematopoietic stem cell for transplantation.
TL;DR: Using a simple prognostic model, patients with high-risk disease who have predictably unfavorable outcome after ASCT and require novel therapeutic approaches can be identified and follow a risk-adapted approach in determining treatment options.
TL;DR: Treatment recommendations based on the evidence are presented in Table 3, entitled Summary of Treatment Recommendations Made by the Expert Panel for Adult Acute Myelogenous Leukemia, and were reached unanimously by a panel of AML experts.
University of Washington1, University of Minnesota2, University of Tennessee Health Science Center3, Food and Drug Administration4, Medical College of Wisconsin5, McMaster University6, University of Texas MD Anderson Cancer Center7, University of British Columbia8, Cincinnati Children's Hospital Medical Center9, Johns Hopkins University School of Medicine10, National Institutes of Health11
TL;DR: The use of consistent standards in clinical trial designs to evaluate agents that have activity in pathogenic pathways could facilitate advances in the treatment of chronic GVHD.
University of British Columbia1, Stanford University2, National Institutes of Health3, University of Michigan4, Brigham and Women's Hospital5, University of Regensburg6, Fred Hutchinson Cancer Research Center7, Harvard University8, Cincinnati Children's Hospital Medical Center9, University of Minnesota10, University of Texas MD Anderson Cancer Center11, Food and Drug Administration12, Johns Hopkins University School of Medicine13
TL;DR: No validated biomarker studies have been established for chronic GVHD, although several candidate biomarkers have been identified from limited hypothesis-driven studies and high-throughput discovery-based methods.
TL;DR: The isolation of CD4+CD25+ T cells with regulatory function from standard leukapheresis products by using a 2-step magnetic cell-separation protocol performed under GMP conditions is described.
TL;DR: Pediatric recipients of unrelated cord blood transplants who underwent transplantation for acute leukemia were sequentially evaluated for their development of antigen-specific T-lymphocyte immunity to herpes viruses and the presence of an antigen- specific response resulted in a relapse-free survival advantage.
TL;DR: Results suggest that allo-RIC is feasible in heavily pretreated HL patients and has an acceptable early transplant-related mortality and both responses observed after the development of GVHD and DLI may suggest a graft-versus-HL effect.
TL;DR: The pathogenesis of alveolar hemorrhage after HSCT is multifactorial, and it is proposed that IAH and DAH in HSCT recipients are related clinical syndromes with similar clinical presentation, risks, and associated high mortality.
TL;DR: Investigation of HLA-haploidentical SCT using nonmyeloablative conditioning, GVHD prophylaxis consisting of tacrolimus and methylprednisolone, and early therapeutic intervention for the GVH reaction suggest that stable engraftment and effectively suppress GV HD in HLA 2-3 antigen-mismatched SCT.
TL;DR: The curative potential of allogeneic HCT after an RIC regimen in patients with SCD is demonstrated and six of 7 patients are stably engrafted off immunosuppression and without sickle cell-related symptoms at 2 to 8.5 years after HCT.
TL;DR: A simple scale combining the KFS and PS enabled separation of high- from low-risk patients, with 6-month cumulative incidences 50% and 15%, respectively for transplant-related mortality and enhanced prognostic power over the CCI alone (P = .018).
TL;DR: Until the effects of pregnancy on the maternal immune system are better understood, it is appropriate whenever possible to avoid parous female donors and to choose male donors for male recipients in HLA-identical related donor SCT.
TL;DR: NST using fludarabine and low-dose intravenous busulfan is a reasonable treatment option for patients with advanced CLL, but that NST earlier in the disease course will likely be needed to achieve long-term disease control in a high proportion of patients.
TL;DR: The observation of similar survival in the patients receiving CMR and those receiving RIR confirms that RIRs are feasible alternatives for high-risk patients with NHL; however, the data suggest that reduced treatment intensity and previous autologous transplantation are associated with increased relapse.
TL;DR: Patients who received voriconazole and sirolimus concomitantly were identified by a review of the medical records of all allogeneic hematopoietic stem cell recipients at this institution from September 1, 2002, to June 1, 2005.
TL;DR: 12 new cases that fit 2 different categories: (1) cases in which clones with characteristics of lymphohemopoietic malignancies were transferred from the donors to the recipients and (2) Cases in which the malignant clone evolved from healthy donor cells once transplanted into the recipient.